| 词条 | Idarubicin |
| 释义 |
| verifiedrevid = 458281600 | IUPAC_name = (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside | image = Idarubicin.svg | image2 = Idarubicin ball-and-stick.png | tradename = | Drugs.com = {{drugs.com|monograph|idarubicin-hydrochloride}} | MedlinePlus = a691004 | pregnancy_US = D | legal_US = Rx-only | routes_of_administration = | bioavailability = | protein_bound = 97% | metabolism = | elimination_half-life = 22 hours | IUPHAR_ligand = 7083 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 58957-92-9 | ATC_prefix = L01 | ATC_suffix = DB06 | ATC_supplemental = | PubChem = 42890 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB01177 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 39117 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = ZRP63D75JW | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08062 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 42068 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1117 | C=26 | H=27 | N=1 | O=9 | molecular_weight = 497.494 g/mol | smiles = O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)C)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = XDXDZDZNSLXDNA-TZNDIEGXSA-N | synonyms = 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione }}Idarubicin {{IPAc-en|ˌ|aɪ|d|ə|ˈ|r|uː|b|ᵻ|s|ɪ|n}} or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.[2] Similar to other anthracyclines, it also induces histone eviction from chromatin.[3] It belongs to the family of drugs called antitumor antibiotics. It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. It is distributed under the trade names Zavedos (UK) and Idamycin (USA). References1. ^{{cite journal |vauthors=Miller JP, Stoodley RJ |title= Studies directed towards anthracyclinone syntheses: The use of d-glucose as a chiral auxiliary in asymmetric Diels–Alder reactions |journal= J. Saudi Chem. Soc. |volume=17 |pages=29–42 |year=2013 |url=http://www.sciencedirect.com/science/article/pii/S1319610311000524 |doi= 10.1016/j.jscs.2011.02.019}} 2. ^Package insert 3. ^{{cite journal |vauthors=Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J |title= Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin |journal= Nature Communications |volume=4 |pages=1908 |year=2013 |url=http://www.nature.com/ncomms/journal/v4/n5/full/ncomms2921.html |pmid= 23715267 |doi= 10.1038/ncomms2921 |pmc=3674280}} External links
2 : Anthracyclines|Topoisomerase inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。